Log in to search using one of your social media accounts:

 

Oral Abstract Presentations
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Source Type: research

Poster Presentations
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Source Type: research

Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia
The treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been revolutionized with the introduction of tyrosine kinase inhibitors (TKIs) and the combination of these agents with chemotherapy. Blinatumomab is a bispecific anti-CD3/CD19 monoclonal antibody with clinical activity as single-agent in the relapsed setting and independent of BCR-ABL1 mutational status, including T315I.The combination of blinatumomab with a TKI may further improve outcomes for this high-risk population including higher eradication of minimal residual disease (MRD) and minimize the use of chemotherapy. (Source: ...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 17, 2017 Category: Hematology Authors: Rita Assi, Hagop Kantarjian, Nicholas J. Short, Naval Daver, Koichi Takahashi, Guillermo Garcia-Manero, Courtney DiNardo, Jan Burger, Jorge Cortes, Nitin Jain, William Wierda, Salim Chamoun, Marina Konopleva, Elias Jabbour Source Type: research

Improving Provision of Care for Long-term Survivors of Lymphoma
The progressive improvement of lymphoma therapies has led to a significant prolongation of patient survival and life expectancy. However, lymphoma survivors are at high risk of experiencing a range of early and late adverse effects associated with the extent of treatment exposure. Among these, second malignancies and cardiopulmonary diseases can be fatal, and neurocognitive dysfunction, endocrinopathy, muscle atrophy, and persistent fatigue can affect patients' quality of life for decades after treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 16, 2017 Category: Hematology Authors: Sabino Ciavarella, Carla Minoia, Angela Maria Quinto, Stefano Oliva, Santa Carbonara, Claudia Cormio, Maria Christina Cox, Elena Bravo, Filippo Santoro, Mariarosaria Napolitano, Michele Spina, Giacomo Loseto, Attilio Guarini Tags: Review Source Type: research

Improving care provision for lymphoma long-term survivors
The progressive improvement of lymphoma therapies has led to a significant prolongation of patient survival and life expectancy. However, lymphoma survivors are at high risk of experiencing a range of early and late adverse effects associated with the extent of treatment exposure. Among these, second malignancies and cardiopulmonary diseases may be fatal, whereas neuro-cognitive dysfunctions, endocrinopathies, muscle atrophy and persistent fatigue can affect patient quality of life even for decades after treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 16, 2017 Category: Hematology Authors: Sabino Ciavarella, Carla Minoia, Angela Maria Quinto, Stefano Oliva, Santa Carbonara, Claudia Cormio, Maria Christina Cox, Elena Bravo, Filippo Santoro, Mariarosaria Napolitano, Michele Spina, Giacomo Loseto, Attilio Guarini Tags: Review Article Source Type: research

Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Real-world Case Series of Consecutive Patients Treated by a Single Multidisciplinary Team in the East of England From 1999 to 2015
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare subtype of lymphoma, with an incidence of  ∼1.5/1,000,000 persons annually.1 Although classified as a subtype of Hodgkin lymphoma (representing 5% of all cases of Hodgkin lymphoma2), NLPHL is a distinct entity from classic Hodgkin lymphoma in terms of the morphologic and immunophenotypic findings and clinical course.1,2 (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 14, 2017 Category: Hematology Authors: Jessica C. Griffin, Shalal Sadullah, Lazlo Igali, Nimish K. Shah, Jennifer Z. Wimperis, Kristian M. Bowles Tags: Case Report Source Type: research

High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement
Systemic non-Hodgkin lymphoma with synchronous central nervous system involvement traditionally carries a poor prognosis. We found encouraging results with the use of high-dose chemotherapy and autologous stem cell transplantation as consolidation for patients in first complete remission. Central nervous system-directed conditioning with a thiotepa-based regimen might reduce the incidence of relapse and improve the outcomes in this population. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 14, 2017 Category: Hematology Authors: David Qualls, Andrew Sullivan, Shuli Li, Andrew M. Brunner, Kerry Collier, Ephraim Hochberg, Philippe Armand, Tracy T. Batchelor, Yi-Bin Chen, Zachariah DeFilipp Tags: Original Study Source Type: research

Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy
In this study we found similar attained dose level and patient outcomes, supporting a role for peg-GCSF with dose-adjusted EPOCH-R. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 14, 2017 Category: Hematology Authors: Prathima Reddy, Sandra Kanan, Andrew Cowan, Houston Warren, Brian Till, Mazyar Shadman, Ryan Cassaday, Oliver Press, Andrei Shustov, Ajay Gopal, Stephen D. Smith Tags: Original Study Source Type: research

Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era
Whether the LMR at relapse can predict clinical outcomes for relapsed/refractory DLBCL in the rituximab era was investigated. We analyzed 74 patients with relapsed/refractory DLBCL initially treated with a rituximab-containing regimen. A low LMR ( ≤2.6) was significantly associated with shortened OS and PFS. The LMR may facilitate better stratification among patients in the low- and intermediate-risk sIPI groups. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 14, 2017 Category: Hematology Authors: Daisuke Katoh, Yotaro Ochi, Tomohiro Yabushita, Yuichiro Ono, Nobuhiro Hiramoto, Satoshi Yoshioka, Noboru Yonetani, Akiko Matsushita, Hisako Hashimoto, Shuichiro Kaji, Yukihiro Imai, Takayuki Ishikawa Source Type: research

Validation of a Molecular Risk Score for Prognosis of Patients with Acute Promyelocytic Leukemia Treated with ATRA and Chemotherapy Containing Regimens
Acute promyelocytic leukemia has become a highly curable disease. Risk stratification remains an important topic to avoid relapse on one hand and unnecessary toxicity on the other hand. We developed and now validated a molecular risk score for APL based on expression levels of three genes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 14, 2017 Category: Hematology Authors: Anna Hecht, Seraphina Doll, Heidi Altmann, Daniel Nowak, Eva Lengfelder, Christoph R öllig, Gerhard Ehninger, Karsten Spiekermann, Wolfgang Hiddemann, Christel Weiß, Wolf-Karsten Hofmann, Florian Nolte, Uwe Platzbecker Source Type: research

High-dose thiotepa, busulfan, cyclophosphamide and autologous stem cell transplantation as upfront consolidation for systemic non-Hodgkin lymphoma with synchronous central nervous system involvement
Systemic non-Hodgkin lymphoma with synchronous central nervous system (CNS) involvement traditionally carries a poor prognosis. We found encouraging results with the use of high-dose chemotherapy and autologous stem cell transplantation as consolidation for patients in first complete remission. CNS-directed conditioning with a thiotepa-based regimen might reduce the incidence of relapse and improve the outcomes in this population. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 14, 2017 Category: Hematology Authors: David Qualls, Andrew Sullivan, Shuli Li, Andrew M. Brunner, Kerry Collier, Ephraim Hochberg, Philippe Armand, Tracy T. Batchelor, Yi-Bin Chen, Zachariah DeFilipp Source Type: research

Nodular Lymphocyte Predominant Hodgkin Lymphoma: A real world case-series of consecutive patients managed through a single MDT in the East of England between 1999 and 2015
Nodular lymphocyte predominant Hodgkin Lymphoma (NLPHL) is a rare subtype of lymphoma with an incidence of around 1.5 per 1,000,000 people per year1. Although classified as a subtype of Hodgkin Lymphoma (representing 5% of all cases of Hodgkin Lymphoma2), NLPHL is a distinct entity from classical Hodgkin Lymphoma (cHL) in terms of morphological/immunophenotypic findings and clinical course(1,2). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 14, 2017 Category: Hematology Authors: J.C. Griffin, S. Sadullah, L. Igali, N.K. Shah, J.Z. Wimperis, K.M. Bowles Tags: Case Report Source Type: research

Peg-GCSF Can be Used with First-Line (da)-EPOCH-R without Compromising Dose Intensity, Safety, or Efficacy
This study finds similar attained dose level and patient outcomes, supporting a role for peg-GCSF with da-EPOCH-R. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 14, 2017 Category: Hematology Authors: Prathima Reddy, Sandra Kanan, Andrew Cowan, Houston Warren, Brian Till, Mazyar Shadman, Ryan Cassaday, Oliver Press, Andrei Shustov, Ajay Gopal, Stephen D. Smith Source Type: research

Increased Mortality Among Patients With Acute Leukemia Admitted on Weekends Compared to Weekdays
This study emphasizes the importance of availability of resources and early presentation to tertiary care centers for acute leukemia patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 8, 2017 Category: Hematology Authors: Kaushal Parikh, Mahek Shah, Dhruv Mehta, Shilpkumar Arora, Nilay Patel, Delong Liu Tags: Original Study Source Type: research

Increased mortality among patients with acute leukemia admitted on weekends as compared to weekdays
The association between weekend admission and patient outcomes has been reported in several acute illnesses, but is unknown in acute leukemia. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 8, 2017 Category: Hematology Authors: Kaushal Parikh, Mahek Shah, Dhruv Mehta, Shilpkumar Arora, Nilay Patel, Delong Liu Source Type: research

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval
The FDA approval of ruxolitinib for intermediate and high-risk myelofibrosis in 2011 changed the therapeutic landscape of the disease. We investigated the first-line treatment choices for MF patients in the pre- and post-ruxolitinib eras and found that the increased use of ruxolitinib has come at the expense of several agents, but has not significantly affected the utilization of hydroxyurea in the first-line setting. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 4, 2017 Category: Hematology Authors: Andrew T. Kuykendall, Chetasi Talati, Najla Al Ali, Kendra Sweet, Eric Padron, David A. Sallman, Jeffrey E. Lancet, Alan F. List, Kenneth S. Zuckerman, Rami S. Komrokji Source Type: research

Generic Imatinib Therapy among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice
This observational study was conducted to assess the efficacy and safety of generic imatinib in 91 patients with chronic myeloid leukemia (either treated first-line or switched from patented to generic imatinib). Efficacy and safety of generic imatinib was comparable to patented imatinib. These results support the use of generic imatinib to reduce healthcare expenditure per patient and increase patient access. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 4, 2017 Category: Hematology Authors: Abdalla Awidi, Salah Abbasi, Kamal Alrabi, Khalid A. Kheirallah Source Type: research

Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec
We retrospectively evaluated 90 patients with chronic myeloid leukemia receiving either upfront original imatinib (OI) or generic imatinib (GI) for the effect of the early molecular response on the long-term outcome. We demonstrated that achieving an optimal response at 3 and 6 months in patients receiving either first-line GI or OI was clearly associated with greater response and event-free survival rates. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 3, 2017 Category: Hematology Authors: Ahmet Emre Eskazan, Sevil Sadri, Dilek Keskin, Mesut Ayer, Bulent Kantarcioglu, Naciye Demirel, Demet Aydin, Fuat Aydinli, Osman Yokus, Isil Erdogan Ozunal, Selin Berk, Fevzi Firat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren, Zafe Tags: Original Study Source Type: research

Outcome of Chronic Myeloid Leukemia Patients with Early Molecular Response at 3 and 6 months: a Comparative Analysis of Generic Imatinib and Glivec
We retrospectively evaluated 90 patients with chronic myeloid leukemia (CML) receiving both upfront original imatinib (OI) and generic imatinib (GI) for the impact of early molecular response on long-term outcome. We demonstrated that achieving optimal response at 3 and 6 months in patients receiving both first-line GI and OI was clearly associated with higher response and event-free survival rates. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 3, 2017 Category: Hematology Authors: Ahmet Emre Eskazan, Sevil Sadri, Dilek Keskin, Mesut Ayer, Bulent Kantarcioglu, Naciye Demirel, Demet Aydin, Fuat Aydinli, Osman Yokus, Isil Erdogan Ozunal, Selin Berk, Fevzi Firat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren, Zafe Source Type: research

Philadelphia Chromosome –like Acute Lymphoblastic Leukemia
Philadelphia chromosome –like acute lymphoblastic leukemia (Ph-like ALL) is a recently described B-cell precursor ALL with a gene expression profile and a high frequency of IKZF1 gene alteration similar to that of Ph-positive ALL. Its prevalence is approximately 12% in children, 21% in adolescents (16-20 years of age), a nd 20% to 24% in adults older than 40 years, with a peak (27%) in young adults 21 to 39 years old. It occurs more often in male individuals and patients with Down syndrome. Ph-like ALL is overrepresented in those with Hispanic ethnicity and is associated with inherited genetic variants in GATA3 (rs3 ...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 1, 2017 Category: Hematology Authors: Ching-Hon Pui, Kathryn G. Roberts, Jun J. Yang, Charles G. Mullighan Tags: SOHO State of the Art Updates and Next Questions Source Type: research

New Series: SOHO ‘State of the Art Updates and Next Questions’
It is with great pleasure that the Society of Hematologic Oncology (SOHO) introduces an exciting new article series in this issue of Clinical Lymphoma, Myeloma and Leukemia, the official journal of the society. The new series entitled, “SOHO State of the Art Updates and Next Questions,” is designed to provide readers with: (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 1, 2017 Category: Hematology Authors: Hagop Kantarjian, Moshe Talpaz Tags: Editorial Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 1, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 1, 2017 Category: Hematology Source Type: research

Vascular Adverse Events During Long-term Nilotinib Therapy in Patients With Chronic Myeloid Leukemia
The treatment of patients with chronic myeloid leukemia in the chronic phase (CML-CP) has changed dramatically in the era of tyrosine kinase inhibitors (TKIs).1 Although most patients will achieve and maintain optimal molecular and cytogenetic responses with TKI therapy, long-term tyrosine kinase inhibition is not without toxicities.2 Cardiovascular events can develop during TKI therapy, mainly in patients with pre-existing cardiovascular disease (CVD) risk factors. Because the life expectancy of patients with CML-CP has increased in this new era, adverse events from TKIs, including CVD, can be challenging for both patient...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 1, 2017 Category: Hematology Authors: Ahmet Emre Eskazan Tags: Letter to the Editor Source Type: research

Vascular adverse events under long-term nilotinib therapy in patients with chronic myeloid leukemia
The management of patients with chronic myeloid leukemia in chronic phase (CML-CP) has changed dramatically in the era of tyrosine kinase inhibitor (TKIs) [1]. Although most of the patients achieve and maintain optimal molecular and cytogenetic responses under TKI therapy, long-term tyrosine kinase inhibition in not without toxicities [2]. Cardiovascular events may develop during TKI therapy mainly in patients with preexisting cardiovascular disease (CVD) risk factors. Since the life expectancy of patients with CML-CP had increased in this new era, adverse events (AEs) of the TKIs including CVDs may be challenging for both...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 1, 2017 Category: Hematology Authors: Ahmet Emre Eskazan Tags: Letter to the Editor Source Type: research

Sepsis and Acute Myeloid Leukemia: A  Population-Level Study of Comparative Outcomes of Patients Discharged From Texas Hospitals
We reviewed outcomes of patients with acute myeloid leukemia (AML) and sepsis in Texas. AML patients (0.25% of> 2 million discharges) had a higher incidence of sepsis (16% vs. 4%) and of sepsis-related mortality (30% vs. 21%), with nearly double the hospital length of stay, compared to non-AML patients with sepsis. This information can increase awareness of the risk of sepsis and the need for early intervention in AML patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 25, 2017 Category: Hematology Authors: Imrana A. Malik, Marylou Cardenas-Turanzas, Susan Gaeta, Gautum Borthakur, Kristen Price, Jorge Cortes, Joseph L. Nates Tags: Original Study Source Type: research

Sepsis and Acute Myeloid Leukemia: A Population Level Study of Comparative Outcomes of Patients Discharged from Texas Hospitals
We reviewed outcomes of patients with acute myeloid leukemia (AML) and sepsis in Texas. AML patients (0.25% of> 2 million discharges) had a higher incidence of sepsis (16% vs. 4%) and of sepsis-related mortality (30% vs. 21%), with nearly double the hospital length of stay, compared to non-AML patients with sepsis. This information can increase awareness of the risk of sepsis and need for early intervention in AML patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 25, 2017 Category: Hematology Authors: Imrana A. Malik, Marylou Cardenas-Turanzas, Susan Gaeta, Gautum Borthakur, Kristen Price, Jorge Cortes, Joseph L. Nates Source Type: research

The clinical spectrum of hepatic manifestations in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world, characterized by the presence of long-lived circulating leukemic cells in the peripheral blood which may infiltrate all organs, particularly those of the reticulo- endothelial system. Liver enlargement and elevation of liver enzymes related to specific involvement by the underlying disease are well-recognized features in these patients. In CLL the differential diagnosis of liver disorders is broad and includes liver infiltration by leukemic cells, immunological manifestations associated with CLL, primary and secondary hepatic malignancies,...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 22, 2017 Category: Hematology Authors: Natalia Kreiniz, Ofrat Beyar Katz, Aaron Polliack, Tamar Tadmor Tags: Review Article Source Type: research

Chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia: a narrative review
The treatment landscape for chronic lymphocytic leukemia (CLL) is changing rapidly. Novel targeted agents such as ibrutinib, venetoclax and idelalisib have made a significant impact on both first line, relapsed/refractory, and high-risk disease. Despite these advances, there are continuous needs for new treatment options, especially for patients who fail or cannot tolerate these novel therapies.In 2011, Porter et al reported the first successful use of autologous chimeric antigen receptor T-cells (CART) directed against CD19 in 3 refractory CLL patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 20, 2017 Category: Hematology Authors: Anthony R. Mato, Meghan C. Thompson, Chadi Nabhan, Jakub Svoboda, Stephen J. Schuster Tags: Review Article Source Type: research

Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
We investigated whether stratifying by the interval between first-line (T1) and second-line (T2) treatments could identify a subgroup of older patients with relapsed CLL/SLL with an expectation of normal overall survival. Longer time-to-T2 was associated with a modestly improved prognosis; however, even among those retreated  ≥ 3 years after T1, survival was poor compared with the general population (5-year relative survival = 50%). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 18, 2017 Category: Hematology Authors: Eric M. Ammann, Tait D. Shanafelt, Melissa C. Larson, Kara B. Wright, Bradley D. McDowell, Brian K. Link, Elizabeth A. Chrischilles Tags: Original Study Source Type: research

Time to second-line treatment and subsequent relative survival in older patients with relapsed CLL/SLL
We investigated whether stratifying by the interval between first-line (T1) and second-line (T2) treatments could identify a subgroup of older patients with relapsed CLL/SLL with an expectation of normal overall survival. Longer time-to-T2 was associated with a modestly improved prognosis; however, even among those retreated ≥3 years after T1, survival was poor compared to the general population (5-year relative survival=50%). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 18, 2017 Category: Hematology Authors: Eric M. Ammann, Tait D. Shanafelt, Melissa C. Larson, Kara B. Wright, Bradley D. McDowell, Brian K. Link, Elizabeth A. Chrischilles Source Type: research

Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up
The present study evaluated the incidence of cardiovascular events (CVEs) in 63 chronic myeloid leukemia (CML) patients after long-term exposure to nilotinib. By considering the effect of cardiovascular risk factors and defining CVEs according to the current 2014 American College of Cardiology/American Heart Association recommendations, the present study attempted to overcome the previous limitations in reporting CVEs in CML patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 15, 2017 Category: Hematology Authors: Nazanin Aghel, Jeffrey Howard Lipton, Eshetu G. Atenafu, Dennis Dong Hwan Kim, Diego Hernan Delgado Tags: Original Study Source Type: research

Cardiovascular Events after Exposure to Nilotinib in Chronic Myeloid Leukemia: Long Term Follow up
This study evaluated the incidence of cardiovascular events (CVEs) in 63 chronic myeloid leukemia (CML) patients after long term exposure to Nilotinib. By considering the effect of cardiovascular risk factors and by defining CVEs based on the current 2014 American College of Cardiology/American Heart Association recommendations, this study attempted to overcome the previous limitations in reporting CVEs in CML patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 15, 2017 Category: Hematology Authors: Nazanin Aghel, Jeffrey Howard Lipton, Eshetu G. Atenafu, Dennis Dong Hwan Kim, Diego Hernan Delgado Source Type: research

Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population
Hairy cell leukemia (HCL) is a rare hematologic malignancy with high response rates and long progression-free survival (PFS) after treatment with purine nucleoside analogs (PNAs; Pentostatin/Cladribine). However, treatment is not curative, and subsequent treatment at relapse is often required. Rechallenge with a purine analog is commonly implemented despite limited data regarding the efficacy of this approach. We retrospectively analyzed 61 consecutive patients with HCL diagnosed between 1995 and 2013 at Cleveland Clinic. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 13, 2017 Category: Hematology Authors: Yazan F. Madanat, Lisa Rybicki, Tomas Radivoyevitch, Deepa Jagadeesh, Robert Dean, Brad Pohlman, Matt Kalaycio, Mikkael A. Sekeres, Mitchell R. Smith, Brian T. Hill Tags: Review Source Type: research

Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era
Whether to clinically approach follicular lymphoma (FL) grade 3 as an indolent or aggressive lymphoma, especially since the introduction of rituximab, is unclear. Our experience with FL grade 3A, compared with FL grade 3B or with concomitant diffuse large B cell lymphoma, primarily treated with R-CHOP suggests possible long-term remissions. This must be confirmed with longer follow-up and additional studies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 13, 2017 Category: Hematology Authors: Moaath Mustafa Ali, Lisa Rybicki, Laila Nomani, Basel Rouphail, Robert M. Dean, Brian T. Hill, Deepa Jagadeesh, Brad Pohlman, Eric D. Hsi, Mitchell R. Smith Source Type: research

Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies
The identification of oncogenic drivers of liquid tumors has led to the rapid development of targeted agents with distinct cutaneous adverse event (AE) profiles. The diagnosis and management of these skin toxicities has motivated a novel partnership between dermatologists and oncologists in developing supportive oncodermatology clinics. Here we review the current state of knowledge of clinical presentation, mechanisms, and management of the most common and significant cutaneous AEs observed during treatment with targeted therapies for hematologic and lymphoid malignancies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 13, 2017 Category: Hematology Authors: Julia D. Ransohoff, Bernice Y. Kwong Tags: Review Article Source Type: research

Long Term Outcomes of Hairy Cell Leukemia Treated with Purine Analogs: a Comparison to the General Population
Hairy Cell Leukemia (HCL) is a rare hematologic malignancy with high response rates and long progression-free survival (PFS) after treatment with purine nucleoside analogs [PNAs; Pentostatin/ Cladribine]. However, treatment is not curative and subsequent treatment at relapse is often required. Re-challenge with a purine analog is commonly implemented despite limited data regarding the efficacy of this approach. We retrospectively analyzed 61 consecutive HCL patients diagnosed between 1995 and 2013 at Cleveland Clinic. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 13, 2017 Category: Hematology Authors: Yazan F. Madanat, Lisa Rybicki, Tomas Radivoyevitch, Deepa Jagadeesh, Robert Dean, Brad Pohlman, Matt Kalaycio, Mikkael A. Sekeres, Mitchell R. Smith, Brian T. Hill Source Type: research

Characteristics of vitamin B12 deficiency in patients with plasma cell disorders
Vitamin B12 deficiency is prevalent among patients with plasma cell dyscrasias (PCDs) but the association is poorly understood. Among 501 patients with PCDs, 20% had low B12. Low B12 was more prevalent in patients with preserved renal function. MCV was not clinically different between low and normal B12 patients and may not be reliable in PCDs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 11, 2017 Category: Hematology Authors: Caitlyn Braschi, John Doucette, Ajai Chari Tags: Original Study Source Type: research

What is the role of chemotherapy in patients with chronic lymphocytic leukemia?
The current standard treatment for patients with chronic lymphocytic leukemia (CLL) who require therapy is chemoimmunotherapy. However, the availability of an increasing number of targeted agents and combination warrants a reassessment of that approach. The high rate of durable responses with ibrutinib in relapsed refractory patients has established its role in this setting; however, because of its impressive efficacy as initial treatment, it should be considered as part of the algorithm in appropriate patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 11, 2017 Category: Hematology Authors: Bruce D. Cheson Tags: Review Article Source Type: research

Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction
The Total Neuropathy Score is ideal for evaluation of bortezomib-induced neuropathy. We used the reduced (TNSr) and clinical (TNSc) forms as well as the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 to assess incidence of neuropathy in patients receiving cyclophosphamide, bortezomib, and dexamethasone as induction for multiple myeloma. Out of 20 evaluable patients, 55%, 40%, and 45% developed neuropathy when assessed by TNSr, TNSc, and NCI CTCAE, respectively. We found wide variation in TNSr and TNSc even when the NCI CTCAE scale reported no progression of neuropathy. (Source: Cl...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 5, 2017 Category: Hematology Authors: Arjun Lakshman, Manish Modi, Gaurav Prakash, Pankaj Malhotra, Alka Khadwal, Sanjay Jain, Savita Kumari, Neelam Varma, Subhash Varma Tags: Original Study Source Type: research

Evaluation of bortezomib induced neuropathy using Total Neuropathy Score (reduced and clinical versions) and NCI CTCAE v4.0 in newly diagnosed patients with multiple myeloma receiving bortezomib-based induction
Total Neuropathy Score (TNS) (reduced and clinical versions) is ideal for evaluation of bortezomib induced neuropathy. We used TNSr and TNSc along with NCI CTCAE v4.0 to assess incidence of neuropathy in patients receiving CyBorD as induction for multiple myeloma. Out of 20 evaluable patients, 55%, 40% and 45% developed neuropathy when assessed by TNSr, TNSc and NCI CTCAE respectively. We found wide variation in TNSr and TNSc even when NCI CTCAE scale reported no progression of neuropathy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 5, 2017 Category: Hematology Authors: Arjun Lakshman, Manish Modi, Gaurav Prakash, Pankaj Malhotra, Alka Khadwal, Sanjay Jain, Savita Kumari, Neelam Varma, Subhash Varma Tags: Original Study Source Type: research

Acute Promyelocytic Leukemia: A perspective
With increased understanding of the mechanisms of carcinogenesis and the dissection of complex, aberrant cellular pathways that underlie neoplastic transformation, it is becoming more clear that diseases once considered morphologically similar are clearly diverse and require specific strategies to achieve response and potentially long term cure. Attacking specific pathways that drive a given cancer exemplifies the precison medicine approach nowhere better characterized than in acute myeloid leukemia (AML) where identification othe characterization ofmolecular aberrations is already leading to the development of novel and m...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 5, 2017 Category: Hematology Authors: Farhad Ravandi, Richard Stone Tags: Perspective Source Type: research

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma
An independent dataset of 91 multiple myeloma patients were tested with eight prognostic mRNA expression signatures. SKY92 best predicted survival (HR = 8.2) and classified the largest fraction (21%) as high risk. Finally 38/91 (42%) cases were low risk by the recently proposed combination SKY92 + ISS achieving a HR 10 for low versus high risk. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 3, 2017 Category: Hematology Authors: Erik H. van Beers, Martin H. van Vliet, Rowan Kuiper, Leonie de Best, Kenneth C. Anderson, Ajai Chari, Sundar Jagannath, Andrzej Jakubowiak, Shaji K. Kumar, Joan B. Levy, Daniel Auclair, Sagar Lonial, Donna Reece, Paul Richardson, David S. Siegel, A. Keit Tags: Original Study Source Type: research

Prognostic validation of SKY92 and its combination with ISS in an independent cohort of Multiple Myeloma patients
Multiple myeloma (MM) is a genetically heterogeneous disease with associated heterogeneous outcomes.[1,2,3,4] In recent years, high risk disease emerged as one of the challenging and unmet needs in the treatment of MM. A number of ongoing and planned studies attempted to develop risk stratified approaches to improve outcomes of high risk MM. To make progress in this area, it is important to accurately and meaningfully identify high risk and low risk MM patients. A number of biomarkers have been proposed to define and elucidate this heterogeneity including genetic and biochemical parameters. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 3, 2017 Category: Hematology Authors: Erik H. van Beers, Martin H. van Vliet, Rowan Kuiper, Leonie de Best, Kenneth C. Anderson, Ajai Chari, Sundar Jagannath, Andrzej Jakubowiak, Shaji K. Kumar, Joan B. Levy, Daniel Auclair, Sagar Lonial, Donna Reece, Paul Richardson, David S. Siegel, A. Keit Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 1, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 1, 2017 Category: Hematology Source Type: research

Defibrotide Use in Vincristine-induced Hepatic Sinusoidal Obstruction Syndrome
We report on a case of HSOS after vincristine administration that was successfully treated with defibrotide. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 30, 2017 Category: Hematology Authors: Catherine Tang, Julian Lindsay, Anthony Gill, Ian Kerridge Tags: Case Report Source Type: research

Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies
Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. To determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 30, 2017 Category: Hematology Authors: Mara Penne, Maryam Sarraf Yazdy, Kruti Sheth Nair, Bruce D. Cheson Tags: Original Study Source Type: research

Extended Follow up of Patients Treated with Bendamustine for Lymphoid Malignancies
Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. In order to determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 30, 2017 Category: Hematology Authors: Mara Penne, Maryam Sarraf Yazdy, Kruti Sheth Nair, Bruce D. Cheson Tags: Original Study Source Type: research

Proteasome Subunit Beta Type 1 P11A polymorphism is a new prognostic marker in multiple myeloma
We retrospectively analyzed the prognostic impact of Proteasome subunit beta type 1 rs12717 polymorphism in 211 consecutively diagnosed multiple myeloma cases. Patients carrying the variant G allele showed significantly shorter progression free survival. In proteasomes of individuals with G/G genotype we found significantly reduced protease activity and lower inhibitory capacity of bortezomib on the caspase- and trypsin-like activity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 30, 2017 Category: Hematology Authors: Gergely Varga, G ábor Mikala, Katalin Piroska Kiss, Éva Kosóczki, Edit Szabó, Nóra Meggyesi, Katalin Balassa, Petra Kövy, Bálint Tegze, Gergely Szombath, Attila Tordai, Hajnalka Andrikovics, László Homolya, Tamás Masszi Tags: Original Study Source Type: research